Clinical trial NCT05046353: D-serine AudRem: R33 Phase
Official title: D-serine Augmentation of Neuroplasticity-based Auditory Learning in Schizophrenia: R33 Phase
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE1
PHASE2
Conditions: Schizophrenia
Schizo Affective Disorder
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
Collaborators: name: Nathan Kline Institute for Psychiatric Research
name: National Institute of Mental Health (NIMH)
First posted: 2021-09-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning.

D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the D-serine treatment over 16 weeks of a program designed to measure auditory plasticity.

Detailed description: D-Serine is a naturally occurring substance in the brain that activates the N-methyl-d-aspartate-type glutamate receptor (NMDAR). This receptor is thought to be important in both schizophrenia and plasticity (learning). My model proposes that problems with NMDAR within the brain leads to impaired plasticity, which in turn leads to impaired cognition. d-serine is an ideal NMDAR activator to study because it balances efficacy, availability and safety. Most d-serine studies have used a low dose, but the evidence for efficacy is even stronger for high dose d-serine, as will be tested in the current study. There has only been limited summary of higher dose d-serine, which is another important reason for this study.

In addition to testing a potentially viable treatment in schizophrenia, a positive result would provide opportunities for use of D-serine in other populations (e.g. anxiety disorders or dementia) and stimulate the pharmaceutical industry to utilize this methodology to assess the efficacy of novel NMDAR modulators, using d-serine as a "gold-standard."

The ultimate goal of this two part grant (R61-R33) study is to improve cognitive remediation by augmenting with D-serine.

We recently completed the R61-phase, meeting our predetermined "milestones. " As predicted, D-serine led to significant enhancement of auditory plasticity and electrophysiological measures.

During the three-year R33-phase, we will conduct a study of D-serine of 60 schizophrenia patients, assessing the effects of D-serine over 16 sessions of this program. Most successful, cognitive remediation programs are limited by lengthy (30-50 hours) treatments. Hypothesizing that adding D-serine will increase efficiency of cognitive remediation, successful completion of the R33-phase is defined as significant improvement in global cognition after 16 hours of treatment, and will serve as a pilot study to determine whether future, definitive clinical trials are warranted.

Eligibility criteria: Inclusion Criteria:

1. Age between 18 and 50
2. DSM-V diagnosis of schizophrenia or schizoaffective disorder
3. Willing to provide informed consent
4. Auditory Cognitive impairment demonstrated by:

   a .MCCB composite domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45) b. And at least one of the following:
5. MCCB verbal memory domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45)
6. Tone matching score of less than or equal to 77.7%
7. Clinically stable for 2 months (CGI less than or equal to 4)
8. Moderate or lower cognitive disorganization (PANSS P2 less than or equal to 4)
9. Medically stable for study participation
10. Willing to use qualified methods of contraception for the study duration and up to 2 months after its end
11. Fluent English speaker
12. Normal hearing
13. Visual acuity corrected to 20/30
14. An estimated Glomerular Filtration Rate (GFR) greater than or equal to 60
15. Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks
16. Judged clinically not to be at significant suicide or violence risk

Exclusion Criteria:

1. Substance abuse (excluding nicotine) within last 60 days
2. ECG abnormality that is clinically significant in the context of study participation in the opinion of the study cardiologist
3. Current clozapine use. Clozapine is excluded for two reasons: to avoid the potential confound of treatment resistant patients and because of clozapine's intrinsic NMDA agonist
4. Participation in study of investigational medication/device within 4 weeks
5. Pregnant women or women of child-bearing potential, who are either not surgically-sterile or for outpatients, using appropriate methods of birth control. Women of child-bearing potential must have a negative serum beta-hCG pregnancy test at screening.
6. Presence of positive history of unstable significant medical or neurological illness
7. Positive toxicology screen for any substances of abuse
8. Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or subjects who represent a significant risk of suicide in the opinion of the investigator

Primary outcomes:
measure: Auditory Cognition
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYSPI
state: New York
Study officials:
References: